

Biomedix® launches PADnet® 4.0

SAINT PAUL, MN - Biomedix, a leader in healthcare risk assessment and information technology (HIT), announced the launch of the newest version of its patented diagnostic device, PADnet. PADnet 4.0 is a vascular assessment system that diagnoses Peripheral Vascular Disease, including Peripheral Artery Disease (PAD) and Chronic Venous Insufficiency (CVI), and expands to securely accept data from other diagnostic devices so additional test results can be aggregated from a single patient encounter.

With the expansion of healthcare into the home and other remote locations, Biomedix redesigned the size, shape and form factor of PADnet to accommodate a variety of field-based applications. The newest version of PADnet is smaller, faster, and features a new mobile-first form factor that easily fits into a backpack.

“Our experience in the Medicare Advantage space confirmed health assessment initiatives require a device that accurately detects PVD while also being portable,” John Romans, CEO of Biomedix shared while discussing the portability features of PADnet 4.0.

In addition, PADnet 4.0 is built with speed in mind. Graham Heaven, Vice President of Sales at Biomedix, commented, “For example, a full arterial study qualifying for reimbursement under CPT code 93923, used to take 25 minutes to complete. Our new PADnet 4.0 system cuts this time in half and can effectively screen patients for disease in less than 5 minutes.”

Research suggests that doctors spend as little as 20% of their time with patients, while spending the rest on paperwork and other administrative tasks. In an effort to change this trend, Biomedix developed a new, web-based platform to enable the scheduling of patients and exchange of patient data with vascular specialists via its patented collaborative framework based on the Biomedix mobile health assessment platform, Remote View™.

PADnet 4.0 also includes wireless connectivity features. “We saw the ability to wirelessly connect to and administer tests with WiFi-enabled devices as a way to increase portability, enable face-to-face interaction between the care provider and patient, generate clinically-valuable data, and facilitate timely counseling and coordinated care with the patient,” commented Chris Trygstad, Network Director at Biomedix.

The shift to a mobile-first platform also required the rethinking of its security platform. “Secure data management for our customers and their patients has always been a top priority,” stated John Romans, “which is why we continue to invest heavily in our cyber security infrastructure.”

Although past versions of PADnet have kept protected health information (PHI) HIPAA-compliant, PADnet 4.0 takes security to a new level through the implementation of a state-of-the-art security infrastructure and storing of all patient data in a secure cloud platform, protecting against device theft and misplacement.

“We’ve seen healthcare organizations make headlines when data breaches occur as a result of a laptop being stolen or misplaced,” said Chris Trygstad, “and we wanted to ensure that doesn’t happen to our customers.”

About Biomedix

Biomedix by Collaborative Care Diagnostics is a leader in healthcare risk assessment and information technology (HIT), enabling care providers to collaborate and cost-effectively save patient limbs and lives. The patented Biomedix information exchange is comprised of easy-to-use, diagnostic devices such as PADnet, which are connected to a secure and HIPAA-compliant cloud-based communication platform that enables PCPs and medical specialists to collaborate in the early detection, treatment, and management of patients with chronic conditions such as peripheral artery disease (PAD) and chronic venous insufficiency (CVI). With over 1,000 active test sites and nearly 1 million studies performed in the US alone, the Biomedix network is positioned to improve clinical outcomes more cost-effectively, on a global scale.

biomedix.com

info@biomedix.com

877-854-0014